Table 1 Clinical characteristics of control subjects and CAD patients
Control Subjects (n = 211) | CAD Patients (n = 211) | |
|---|---|---|
Age, years | 66 ± 10 | 66 ± 11 |
Body mass index, kg/m2 | 23.4 ± 2.9 | 24.9 ± 3.5* |
Smoking, n(%) | 29(13) | 51(24)* |
A-FABP (ng/mL) | 15.1 (11.7-19.9) | 20.6 (15.7-27.8)* |
Diabetes Mellitus, n(%) | 39(18) | 116(55)* |
FBS (mg/dL) | 98(92-109) | 104(95-126)* |
Hypertension, n(%) | 65(31) | 156(72)* |
Dyslipidemia, n(%) | 83(39) | 162(77)* |
LDL-C (mg/dL) | 105(85-122) | 124(97-134)* |
HDL-C (mg/dL) | 58 ± 12 | 43 ± 11* |
Triglycerides (mg/dL) | 126 (105-151) | 129(90-170) |
eGFR(ml/min/1.73 m2) | 75.6 ± 17.6 | 66.9 ± 18.1* |
hsCRP(mg/L) | 0.67(0.29-1.68) | 1.62(0.60-3.02)* |
Medications | ||
ACEI/ARBs | 28(13) | 82(39)* |
CCBs | 44(21) | 91(43)* |
Diuretics | 18(9) | 30(14) |
β-blockers | 23(11) | 54(26)* |
Statins | 55(26) | 126(60)* |
Thiazolidinediones | 15(7) | 23(11) |